Fibulin-1 (Fbln-1) is an immunogenic breast cancerrelated glycoprotein identified by serological analysis of cDNA expression library (SEREX) strategy. Here, we show that dendritic cells from two breast cancer patients elicited a CD4
Introduction
The recent development of molecular techniques to analyse immune reactivity to cancer cells at the gene level has led to the identification and characterization of a large number of human tumour antigens (ags) recognized by antibodies and T cells Rosenberg, 2001; Parmiani et al., 2002) . Application of these techniques has led to the identification of new targets for gene therapy of human neoplasms. Among these techniques, the SEREX method was the most successful approach for cloning immunogenic tumour ags recognized by B cells, and about 1700 genes have thus far been identified (Sahin et al., 1995 (Sahin et al., , 1997 Struss et al., 2001; Forti et al., 2002) . Despite this wealth of tumour ags, only four SEREXdefined ags (tyrosinase, NY-ESO-1, coactosin-like protein and MAGE-1) were shown to elicit both cellular and humoral immune responses to tumour cells (Van der Bruggen et al., 1991; Brichard et al., 1993; Jager et al., 1998 Jager et al., , 2000 Nakatsura et al., 2002) . Using SEREX, we recently demonstrated that fibulin-1 (Fbln-1) is a breast cancer-restricted ag able to induce specific antibody immunity that can be exploited as a tool for early detection of breast cancers (Forti et al., 2002; Pupa et al., 2002a) .
Fbln-1 is a member of an emerging family of glycoproteins found in extracellular matrix (ECM) and blood (Argraves et al., 1990) . Alternative splicing of Fbln-1 precursor RNA results in the expression of four transcripts that encode overlapping polypeptides, designated A-D, which differ only in their carboxy-terminal domains . The biologic functions of these transcripts appear to be variant-specific (Moll et al., 2002) . Fbln-1 can self-associate and bind to ECM proteins, including fibronectin, laminin and nidogen, and to the coagulation protein fibrinogen (Hayashido et al., 1998) . Fbln-1 is found in basement membranes and in loose connective tissue associated with matrix fibres (Roark et al., 1995) .
Several studies have implicated Fbln-1 as having a role in cancer (Qing et al., 1997; Twal et al., 2001; Du et al., 2002; Moll et al., 2002; Greene et al., 2003) . An elevated expression of Fbln-1 is associated with human breast tumours (Forti et al., 2002; Greene et al., 2003) . Fbln-1 inhibits in vitro adhesion and motility of various carcinoma cell lines (Twal et al., 2001) . Fbln-1 also suppresses the growth of human fibrosarcomas in nude mice (Qing et al., 1997) and human papillomavirus E6-mediated transformation (Du et al., 2002) .
Here, we report both Fbln-1-specific humoral and cellular immune responses in a few breast carcinoma patients. This finding, together with the results from the immunohistological analysis of Fbln-1 expression in 528 primary breast carcinomas and survival analysis, suggests the possible involvement of Fbln-1 in triggering protective antitumour immune responses.
Results

Immunogenicity of Fbln-1 in breast carcinoma patients
Immunoprecipitation analysis was performed using sera from four breast carcinoma patients and SKBR-3 cell extracts. Immunoprecipitates were analysed by Western blotting using anti-Fbln-1 MAb MEM-2. A polypeptide having molecular mass consistent with that of Fbln-1 (B74 kDa) was detected using GV patient serum ( Figure 1a , lane 3) or PZ serum (data not shown) or anti-Fbln-1 MAb ( Figure 1a , lane 1), but not using CM serum (Figure 1a lane 2), and only weakly using MZ serum (data not shown). To evaluate whether Fbln-1 could encode T-cell epitopes, we tested IFN-g release by the ELISPOT assay on T cell lines selected in vitro from two breast cancer patients (GV and PZ) by dendritic cell (DC)-mediated antigen (ag) presentation. The functional assay was performed after T cell culture for 2/3 weeks with autologous myeloid DCs loaded with killed lymphoblastoid cell line (LCL), as a positive control of APC function (Figure 1b ), or loaded with either Fbln-1 or recombinant soluble HER-2 proteins as control ( Figure 1c) . From both patients, an Fbln-1-specific release of IFN-g was observed by the T cell lines selected against such protein (Figure 1c) . In addition, a T cell line from patient GV selected against the control protein HER-2 recognized HER-2-loaded DCs, but not Fbln-1-loaded DCs (Figure 1c ). To identify the T-cell subset(s) responsible for the observed Fbln-1-specific response, T cell lines from seropositive (GV) and seronegative (CM) breast cancer patients were selected by culture for 2 weeks with Fbln-1-loaded DCs and then assessed for intracellular cytokine production. A fourcolour flow cytometry assay allowed the simultaneous detection of IFN-g and IL-4 production in either the CD4 þ or the CD8 þ T-cell subset (Figure 2 ). This assay revealed an Fbln-1-specific production of IFN-g, IL-4 or both cytokines, mainly in the CD4 þ subset of patient GV, with only a weak response in the CD8 þ fraction, compared to empty DCs or to DCs loaded with a control protein (recombinant soluble HER-2 receptor). No Fbln-1 T-cell-mediated immune response was observed in the seronegative patient CM (Figure 2) , and also in patient MZ (data not shown). By the same intracellular cytokine production assay, a pattern of Fbln-1-specific cytokine response, consistent with three functional CD4 þ subsets, T-helper (TH)1, TH2 and TH0 was observed, after DC-mediated selection, even in the other responsive patient (patient PZ) out of four tested (data not shown).
Fbln-1 transcripts and protein isoforms in breast carcinoma cell lines RT-PCR was performed to evaluate the profile of Fbln-1 splice variants expressed in the human breast carcinoma . Western blot analysis was performed using antihuman Fbln-1 MAb MEM-2. (b) Short-term T cell lines from patient GV, after culture for 2 or 3 weeks with autologous myeloid DCs loaded with killed autologous LCL, were tested for IFN-g production in response to empty DCs (white histograms), killed LCL-loaded DCs (dashed histograms) or live LCL (gray histograms). (c) Short-term T cell lines from patients GV and PZ, after selection on protein-loaded DCs, were tested for IFN-g production in response to DCs loaded with Fbln-1 (filled histograms) or HER-2 (empty histograms). Statistical analysis (ANOVA followed by SNK test) was annotated as follows: *: Po0.05; **: Po0.01; ***: Po0.001
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lines SKBR-3 and MDA-MB-157, and both Fbln-1C and -1D transcripts were found ( Figure 3a) . The same pattern of results was confirmed in other human breast carcinoma cell lines and specimens (data not shown). These data were consistent with findings from the Western blot analysis (Figure 3b) , showing that the cells expressed two major Fbln-1 immunoreactive polypeptide bands migrating at approximately 74 and 72 kDa (Figure 3b ). Confocal microscopy analyses of MCF-7 human breast carcinoma cells not only localized the Fbln-1 protein mainly within the cells but also at the cell surface ( Figure 3c and 3d, respectively). The same pattern of Fbln-1 expression, investigated both by confocal microscopy and flow cytometry on live and fixed tumour cells, was also found in SKBR-3 and MDA-MB-157 cells (data not shown).
Fbln-1 expression in primary breast carcinomas
Immunohistochemical analysis of a series of 528 primary breast carcinomas with 3A11 MAb, which recognizes all Fbln-1 isoforms, revealed the expression of Fbln-1 in 35% of the cases. Based on this analysis, three categories were distinguished: tumours that displayed no Fbln-1 staining, ones that expressed weak intracellular staining and ones that expressed strong Fbln-1 staining (Figure 4 ). In general, weak or no staining was present in the surrounding stroma (Figure 4 ). Normal mammary epithelial cells showed no Fbln-1 staining (data not shown). Tumour specimens that were grouped into these categories were correlated with other pathobiological variables, which are tabulated in Table 1 . w 2 analysis for trend indicated a statistically significant association between Fbln-1 expression and the lack of cathepsin D expression (P ¼ 0.04) in tumour specimens. Borderline associations of Fbln-1 expression were observed with the absence of laminin receptor expression (P ¼ 0.06) and with a low mitotic index (P ¼ 0.06).
Survival analysis according to Fbln-1 expression
When long-term overall survival was analysed according to Fbln-1 expression (weak and strong staining vs negative staining), no differences were observed ( Figure 5a ). In the same cohort of patients, lymphoid infiltrate (LI) was found to be weakly associated with survival (Me´nard et al., 1999) . When cases were separated according to the presence or absence of LI at the tumour site ( Figure 5b and c, respectively), in patients with LI-positive tumours, Fbln-1 expression was associated with improved survival, whereas in patients without LI, Fbln-1 was associated with poorer survival. While these differences in overall survival were not found to be statistically significant, at long-term analysis (12 years), borderline significances were observed (P ¼ 0.04 in LI-negative and P ¼ 0.09 in LIpositive) (Figure 5b and c), indicating an inverse prognostic role of Fbln-1 according to LI. 
Discussion
The results of this study provide evidence for an integrated immune response to Fbln-1, a previously SEREX-defined breast cancer-related antigen (Forti et al., 2002) . In fact, an Fbln-1-specific CD4 þ response was elicited in two patients with a high (GV) and moderate (PZ) antibody response to this antigen. No CD4 þ response was revealed in one Fbln-1-seronegative patient (CM patient) and in a patient (MZ) with low levels of anti-Fbln-1 antibody.
Monocyte-derived Fbln-1-loaded DCs, induced to maturation by TNF-a, activated three distinct subsets (TH1, TH2 and TH0) of Fbln-1-specific CD4 þ T cells. This finding is consistent with the known functional plasticity of myeloid DCs as inducers of both TH1 and TH2 polarization in naı¨ve TH cells (Liu et al., 2001; Lutz and Schuler, 2002) . While the IFN-g-positive subset might be relevant in providing help for the induction of cytotoxic T lymphocytes, the IL-4-positive subset indicates a TH2 response to Fbln-1, consistent with a helper activity on antibody production, in agreement with the high antibody response to Fbln-1 found in one of the patients. Furthermore, after APCmediated T-cell activation, we detected mainly CD4 þ -and weak CD8 þ -mediated responses to Fbln-1. A preliminary screening of Fbln-1D and -1C sequences (performed at http://syfpeithi.bmi-heidelberg.com/) for peptides containing binding motifs for the most frequent HLA class I alleles returned several possible epitopes with binding scores similar to other known human tumour epitopes (such as MAGE or several melanomaassociated ags). Clearly, assessment of CD8 þ T-cellmediated response to Fbln-1 awaits analysis of additional patients with distinct HLA class I alleles.
RT-PCR analysis and Western blotting indicated that several human breast carcinoma lines, including SKBR-3 and MDA-MB-157 cells, express the Fbln-1C and -1D splice variant transcripts and translation products. Our findings also suggest that the immunogenic form of Fbln-1 is the D isoform since only the D isoform was cloned during the SEREX analysis (Forti et al., 2002) ; and immunoprecipitation of SKBR3 cell extract with GV patient's serum (Figure 1a) suggests the recognition of only one band migrating with an electrophoretic mobility consistent with that of the D isoform. Expression of the 2.7-kb Fbln-1D transcript along with the 2.4-kb Fbln-1C mRNA has been consistently detected in various types of cells . The two isoforms share a common 566-amino-acid N-terminal segment and differ in their C-termini. However, it (Greene et al., 2003) . A further mechanism might be the imbalance in expression between Fbln-1 isoforms, a possibility supported by the finding of an increased Fbln-1C : Fbln-1D mRNA ratio observed in ovarian cancer cells compared to normal ovaries and benign tumours (Moll et al., 2002) . Moreover, in our immunohistochemical analysis, tumour stroma was almost completely negative, suggesting that the serologically recognized epitope is not available when Fbln-1 is associated with other ECM molecules. This raises the possibility that immunogenicity of Fbln-1 in breast cancer patients rests in overproduction of the D isoform by tumour cells and the failure of this protein to become associated with ECM. Testing of this possibility awaits purification of patient antibodies and evaluating their Fbln-1 isoform specificity.
Our detection of Fbln-1 expression at the cell surface of several breast cancer cell lines raises the possibility for targeting this ag for antibody-based immunotherapeutic approaches, provided that the anti-Fbln-1 antibodies will not recognize matrix-associated or plasma Fbln-1 glycoprotein.
Biologic and pathologic features of 528 breast carcinomas, evaluated according to the absence, low and elevated levels of Fbln-1 expression, showed no strong associations. Only the expression of the 67 kDa LR (Me´nard et al., 1999) and cathepsin D (Niu et al., 2002) , two molecules involved in ECM remodelling and whose expression in tumours is associated with aggressiveness (Pupa et al., 2002b) , was weakly associated with the absence of Fbln-1 expression. Overall survival analysis evaluated according to Fbln-1 expression showed that this glycoprotein is not associated with prognosis. However, the Fbln-1 isoforms detected in our retrospective series are unknown. In fact, the antibody used reacts with an epitope at the N-terminus, shared by all Fbln-1 isoforms, and our data indicate that breast carcinoma may express both C and D isoforms. Although coordinated expression of these two isoforms has been described , abnormal differential expression of the two isoforms in tumour tissues cannot be excluded. Since the two isoforms appear to have an opposite effect on tumour aggressiveness (Clinton et al., 1996; Qing et al., 1997; Roger et al., 1998; Twal et al., 2001; Du et al., 2002) , the failure to discriminate the isoforms expressed in our series might have masked any impact on survival. The availability of isoform-specific reagents will enable analyses of potentially altered expression of the two isoforms.
In conclusion, we demonstrated that the SEREXdefined molecule Fbln-1 is able to elicit both cellular and humoral immune responses in breast cancer patients. Furthermore, the finding that Fbln-1 expression is associated with improved survival in patients with LI at the tumour site suggests the possible involvement of Fbln-1 in triggering protective antitumour immune responses.
Materials and methods
Cell lines
Human breast carcinoma cell lines SKBR-3, MCF-7 and MDA-MB-157 were obtained from the ATCC (Rockville, MD, USA). Cells were grown in RPMI 1640 medium (Sigma, St Louis, MO, USA) containing 10% (v/v) foetal calf serum (FCS) (Sigma) and L-glutamine in a humidified chamber (95% air, 5% CO 2 ) at 371C.
Antibodies
Mouse monoclonal antibodies (MAbs) anti-Fbln-1, MEM-2 and 3A11 have been described previously Pupa et al., 2003) . MAb anti-HER-2 (cB11) was purchased from Ylem (Avezzano, AQ, Italy). MAb anti-p53 (DO7), MAb anti-bcl2 (100) and rabbit polyclonal anticathepsin D were purchased from Novocastra (Newcastle-upon-Tyne, UK). MAb antiprogesterone receptor (1A6) was purchased from DBA (Segrate, MI, Italy). MAb anti-67Kd laminin receptor (MLuC5) has been described previously (Martignone et al., 1992) .
Immunoprecipitation and Western blotting
SKBR-3 cells were lysed for 45 min on ice in lysis buffer (50 mM Tris-HCl pH 7.2, 150 mM NaCl, 1 mM EDTA, 1% Triton X-100, 0.1% SDS and 0.5% deoxycholic acid) containing protease inhibitors, 2 mM phenylmethylsulphonylfluoride (PMSF) and 10 mg/ml aprotinin as described (Qing et al., 1997) . Lysates were clarified by centrifugation at 15 000 Â g for 15 min. Clarified lysates were precleared for 30 min at 41C with Immunopure Immobilized Protein A/G Sepharose (Pierce, Rockford, IL, USA), equilibrated in lysis buffer. Protein concentration was determined by the BCA protein assay (Pierce).
Aliquots of protein A/G-Sepharose (20 ml equilibrated in lysis buffer) were incubated for 2 h at 41C with either MAb MEM-2 (diluted 1 : 100) or with the sera of breast cancer patients (diluted 1 : 20). The Sepharose bound-immune complexes were washed three times with lysis buffer and incubated with the clarified SKBR-3 cell extracts (2 mg SKBR-3 protein/ sample) on a rocker for 3 h at 41C.
Sepharose-bound immunecomplexes were washed three times with lysis buffer, eluted and denatured by heating for 7 min at 951C in reducing Laemmli sample buffer. The samples were resolved on 10% polyacrylamide gels and the separated proteins electrophoretically transferred onto nitrocellulose membranes (Hybond C, Amersham Biosciences, Little Chalfont, UK). Membranes were incubated at room temperature for 1 h with MAb 3A11 followed by incubation at room temperature for 1 h with biotinylated anti-mouse Ig speciesspecific whole antibody (1 : 400) and streptavidin-horseradish peroxidase (HRP) conjugate (1 : 1500) (Amersham), and visualized using the ECL detection system (Amersham).
RT-PCR analysis
RNA was extracted with RNAzolt B isolation solvent (TelTest, Inc., Friendswood, TX, USA). Reverse transcription was carried out at 421C for 60 min using 2 mg of total RNA, 75 pmol of oligo(dT) primer, 0.5 mM of each dNTP and 50 U of MMLV reverse transcriptase (Invitrogen, Carlsbad, CA, USA). PCR was performed in a total volume of 50 ml using the following sequence-specific primer pairs: Fbln-1, ( þ ) primer (expected product 479 bp). After an initial denaturation step at 951C for 3 min, PCR was carried out at 951C for 1 min, 561C for 2 min and 721C for 2 min for 30 cycles, followed by final extension at 721C for 10 min. Amplification of glyceraldehyde-3-phosphate dehydrogenase (GAPDH) transcripts was performed in a 20-cycle PCR using ( þ ) primer 5 0 -TCCAC CACCCTGTTGCTGTA-3 0 and (-) primer 5 0 -ACCACAGTC CATGCCATCAC-3 0 .
T cell response to Fbln-1-loaded DCs
Informed consent for leukapheresis and serum samples was obtained from the four reported breast cancer patients (GV, CM, PZ and MZ). Peripheral blood mononuclear cells from breast cancer patients were isolated by centrifugation of blood samples on Ficoll gradients (Hypaque; Pharmacia, Uppsala, Sweden), resuspended in RPMI 1640 medium-10% pooled human serum (PHS) and allowed to adhere for 2 h at 371C in 150-cm 2 culture flasks (Corning). The adherent fraction (490% CD14 þ ) was used to generate immature myeloid DCs by culture with recombinant human granulocytemacrophage colony-stimulating factor (rHuGM-CSF) (50 ng/ ml, Mielogen, Schering-Plough, Milan, Italy) and IL-4 (20 ng/ ml, PeproTech, Rocky Hill, NJ, USA) as described (Sallusto and Lanzavecchia, 1994) . Immature DCs were cultured for 24 h in the presence of human Fbln-1 (20 mg/ml), prepared as previously described (Twal et al., 2001) , or in the presence of a control ag (recombinant soluble HER-2 protein, 50 mg/ml, kindly provided by Dr Y Yarden). As a positive control for ag presentation by DCs, patients' T lymphocytes were cultured with autologous DCs loaded with killed (by two cycles of freeze-thaw) autologous LCL. DCs' maturation was then promoted by culture for 24 h in the presence of TNF-a (20 ng/ ml). DCs exposed to Fbln-1, HER-2 or killed LCL were then used to stimulate autologous peripheral blood lymphocytes (PBLs) by coculture at a lymphocyte:DC ratio of 10 : 1 in the presence of IL-2 (10 U/ml). After two or three weekly rounds of restimulation with DCs, the resulting T cell lines were assessed for ag-specific response by either IFN-g ELISPOT and intracellular cytokine production by flow cytometry. IFNg ELISPOT was performed in 96-well Multiscreen HA plates (Millipore, Bedford, MA, USA). To this end, plates were coated at 41C, overnight, with 15 mg/ml of 1-D1K anti-IFN-g MAb (Mabtech, Stockholm, Sweden) in NaHCO 3 0.1 M, pH 9.6 solution. Plates were then seeded with decreasing concentrations (20 000-5000 cells/well) of lymphocytes from T-cell cultures, and with 10 000 cells/well of autologous DCs either empty or loaded with proteins (Fbln-1 or HER-2), or with killed LCL in RPMI-1640, 10% PHS. Phytoemoagglutinin (PHA) (1%), or 20 ng/ml phorbol myristate acetate (PMA, Sigma-Aldrich, St Louis, MO, USA) plus 500 ng/ml ionomycin (Sigma-Aldrich) were used as positive controls for the T-cell response in the ELISPOT assay. After incubation at 371C for 24 h, plates were washed with phosphate-buffered saline (PBS) and labelled for 2 h at room temperature with 1 mg/ml of biotin-conjugated secondary anti-human IFN-g 7B6-1 MAb (Mabtech). After washing with PBS, streptavidin-ALP (Mabtech) diluted 1 : 1000 was added and the plates were incubated for 1 h. Finally, plates were developed with alkaline phosphatase-conjugate substrate kit (Bio-Rad Laboratories, Hercules, CA, USA). After 30 min, the colorimetric reaction was terminated by washing with tap water. After air-drying of the plates, spots in each well were evaluated by the AID Elispot reader (Autoimmun Diagnostika GmbH, Strasburg, Germany). The number of spots produced by T cells in response to empty DCs was o10% of the number of spots obtained in response to Fbln-1 or HER-2-loaded DCs and was subtracted from the latter value. To assess the intracellular production of IFN-g and/or IL-4 in response to DCs exposed to Fbln-1 or HER-2, T cell lines were cultured with DCs for 4 h. After the first hour, GolgiStopTM (BD Pharmingen, San Diego, CA, USA) was added. Cell surface staining was carried out with fluorescein isothiocyanate (FITC)-anti-CD4 and PerCP-anti-CD8 MAbs (Becton Dickinson, Milan, Italy), followed by fixation with paraformaldehyde, permeabilization with Perm/WashTM (BD Pharmingen) and staining with allophycocyanin-anti-IFN-g and phycoerythrin (PE)-anti-IL-4 MAbs (BD Pharmingen) in the presence of Perm/WashTM solution. Cells were analysed by four-colour flow cytometry carried out in a dual-laser FACScalibur cytofluorimeter (Becton Dickinson) with Cellquest software.
Confocal microscopy
MCF-7 cells were grown on glass coverslips for 3 days and fixed in 4% buffered paraformaldehyde for 10 min on ice. After washing with PBS pH 7.4 containing 0.2% Triton X-100, coverslips were incubated with MEM-2 primary antibody (1 : 100) for 1 h at room temperature and with Alexa 488-conjugated goat anti-mouse IgG (Molecular Probes Inc., Eugene, OR, USA) (1 : 1000) for 45 min at room temperature. After three washes in PBS, coverslips were mounted on glass slides for microscopy using Mowiol (Calbiochem, San Diego, CA, USA) and observed with a confocal microscope (Microradiance 2000; Bio-Rad Laboratories Inc., Hercules, CA, USA) equipped with argon (488 nm) and HeNe (543 nm) lasers. Images were analysed using Lasersharp 2000 software. Control cells were exposed to relevant secondary antibodies alone and showed no significant degree of labelling. For cell surface labelling, live MCF-7 cells were gently shaken in PBS for 2 h at room temperature and processed as described above. After the final incubation, cells were fixed in 4% buffered paraformaldehyde for 10 min on ice and mounted in Mowiol onto alcohol-washed slides.
Tissue samples
Breast tissue samples from 528 patients operated on in 1978 and 1979 at the Istituto Nazionale per lo Studio e la Cura dei Tumori for primary duct, lobular or mixed infiltrating breast carcinoma were studied. Haematoxylin-eosin-stained histologic slides of each specimen included in the study were reviewed for diagnostic reassessment of the histotype, grading, necrosis and LI. LI, evaluated morphologically, was scored positive when a dense or moderate cellular population was present, and negative when only occasional inflammatory cells were found. Histologic grading was performed as described (Pereira et al., 1995) , based on tubule formation, nuclear morphology and number of mitoses. The latter was scored positive for more than one mitosis per high-power field and negative for one or less mitosis per high-power field after analysis of at least 10 microscopic fields at Â 400 magnification. The presence or absence of non-comedo necrosis was also recorded.
Immunohistochemistry
Immunohistochemical staining was performed on Bouinfixed, paraffin-embedded tissue sections using a peroxidasestreptavidin method. Endogenous peroxidase activity was blocked by treatment with 0.3% hydrogen peroxide in methanol for 30 min. For Fbln-1 staining tissue sections were treated with normal goat serum (1 : 50) for 30 min at room temperature. 3A11 MAb (20 mg/ml) was incubated for 1 h followed by biotinylated anti-mouse IgG and HRP-conjugated streptavidin (Dako, Glostrup, Denmark). Peroxidase activity was detected by using the chromogenic substrate diaminobenzidine. Fbln-1 staining was scored as weakly positive, strongly positive or negative according to the intensity of immunostaining. Homogeneous staining was found in almost all the tumours and those that were heterogeneous were scored positive when more than 10% of tumour cells were immunoreactive.
Statistical methods
The association between Fbln-1 expression in tumour tissues and pathological/biomolecular parameters was evaluated using the Cochran-Armitage trend test. Percent survival at 12 years was evaluated using the w 2 test. The actuarial probability of mortality was estimated by Kaplan-Meier analysis, and differences were assessed using the log-rank test. All statistical tests were two-tailed (significance Po0.05) and performed using SAS software (SAS Institute Inc., Cevy, NC, USA). The results of Elispot assay were evaluated by Anova followed by Student-Newman-Keuls (SNK) test.
